Teva Pharmaceutical (TEVA)
NYSE:TEVA
Want to see TEVA full AI Analyst Report?
TEVA Stock Chart & Stats
$31.61
$0.18(0.83%)
At close: 4:00 PM EST
$31.61
$0.18(0.83%)
Day’s Range― - ―
52-Week Range$13.04 - $37.35
Previous CloseN/A
Volume1.13M
Average Volume (3M)6.72M
Market Cap
$36.66B
Enterprise Value$50.36B
Total Cash (Recent Filing)$3.56B
Total Debt (Recent Filing)$17.38B
Price to Earnings (P/E)25.4
Beta0.69
Next Earnings
Apr 29, 2026EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.96
Shares Outstanding1,164,638,700
10 Day Avg. Volume4,085,694
30 Day Avg. Volume6,721,150
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.53
Price to Sales (P/S)2.08
P/FCF Ratio31.24
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue2.92
Enterprise Value/Gross Profit5.63
Enterprise Value/Ebitda15.96
Forecast
1Y Price Target
$39.57Price Target Upside25.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)2.7
Revenue Forecast (FY)$16.62B
Bulls Say, Bears Say
Bulls Say
Clinical DataAnalyst highlights that duvakitug's clinical update shows top-tier efficacy and maintained response with monthly maintenance dosing, supporting strong commercial potential versus competing biologics.
Non-dilutive FinancingAnalyst notes that the Royalty Pharma partnership provides substantial non-dilutive funding to accelerate the IL15 program without materially burdening company profitability.
R&D CapabilityAnalyst cites the company's internally discovered TL1A target and broader R&D engine as a source of potential long-term value that could deliver meaningful upside beyond current marketed products.
Bears Say
Competitive PositioningAnalyst warns that pivotal trials for duvakitug remain ongoing and the drug trails a first-mover, which could constrain market share and delay commercial uptake.
Conflicts Of Interest In ResearchAnalyst points out disclosed business and financial relationships between the reporting firm and the company, creating potential conflicts of interest that could undermine report objectivity and investor trust.
Earnings Risk From MarginsAnalyst cautions that consensus revenue estimates may not fully reflect margin pressures, creating risk of earnings downside if margins come in weaker than expected.
Teva Pharmaceutical News
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $13.04 and its highest was $37.34 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $36.66B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Apr 29, 2026 which is in 13 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Jan 28, 2026. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.641 by $0.319.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.48.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,164,638,700 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.96 in its last earnings report, beating expectations of $0.641. Following the earnings report the stock price went up 2.09%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Currently, no hedge funds are holding shares in TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teva Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.57 (25.18% Upside)
$39.57 (25.18% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 30.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.60%
12-Months-Change
Fundamentals
Return on Equity
20.09%
Trailing 12-Months
Asset Growth
3.61%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Company Deck
TEVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong progress on the company’s Pivot to Growth: double-digit growth in key innovative brands, improved gross margins, meaningful pipeline validation and clear deleveraging progress. These positives were tempered by dependency on a $500M milestone for headline Q4 growth, a flat generics business with regional softness, near-term one-time inventory/gross-to-net effects that complicate comparability, higher OpEx pressure and persistent clinical/catalyst risk. On balance the strong commercial momentum, improving margin profile and validated pipeline catalysts outweigh the transitory one-time effects and execution risks.View all TEVA earnings summariesTEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
$39.57
▲(25.18% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Amneal Pharmaceuticals
―
Ownership Overview
0.49% Insiders
5.64% Mutual Funds
0.02% Other Institutional Investors
89.41% Public Companies and Individual Investors